[ad_1]
It suspended testing of the US pharmaceutical giant Johnson and Johnson’s coronavirus vaccine on Monday after a health problem emerged in one of the test subjects.
The company is one of those competing to be the first to produce a vaccine against the disease.
Currently, trials are underway in the final part of a three-phase clinical trial, and the vaccine is being administered to thousands of people to test its efficacy and safe use.
Johnson and Johnson said last month that it intends to involve 60,000 people on three continents in the third phase of the experiments.
However, a report said Monday that diseases, even serious ones, usually occur during a clinical trial and are expected to show up in large numbers in larger trials.
It was also found that there is a difference in announcing the suspension of trials at the trial level than when a health authority orders the same.
The company highlighted its strong commitment to the safe use of the vaccine. He also noted that the company’s doctors and health professionals from independent inspection bodies are investigating the subject’s illness.
Cover photo illustration.
[ad_2]
